Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 65/100

Failure Rate

16.7%

2 terminated/withdrawn out of 12 trials

Success Rate

75.0%

-11.5% vs industry average

Late-Stage Pipeline

17%

2 trials in Phase 3/4

Results Transparency

0%

0 of 6 completed trials have results

Key Signals

4 recruiting

Enrollment Performance

Analytics

Phase 2
10(83.3%)
Phase 4
2(16.7%)
12Total
Phase 2(10)
Phase 4(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (12)

Showing 12 of 12 trials
NCT07553637Phase 2Recruiting

ALTO-207 in Adults With Treatment-resistant Depression (TRD)

Role: lead

NCT06391593Phase 2Completed

PD, PK, and Safety of ALTO-203 in Patients With MDD

Role: lead

NCT06502964Phase 2Recruiting

Study of ALTO-101 in Patients With Schizophrenia

Role: lead

NCT05712187Phase 2Completed

Phase 2b Study of ALTO-100 in MDD

Role: lead

NCT05922878Phase 2Recruiting

Study of ALTO-300 in MDD

Role: lead

NCT06656416Phase 2Recruiting

ALTO-100 in Bipolar Disorder With Depression (BD-D)

Role: lead

NCT05118750Phase 2Completed

ALTO-300 in Depression

Role: lead

NCT05157945Phase 2Completed

ALTO-300 in Depression (ALTO-300-004)

Role: lead

NCT05419869Phase 2Completed

Pilot Decentralized Trial

Role: lead

NCT05117632Phase 2Completed

ALTO-100 in MDD and/or PTSD

Role: lead

NCT04388189Phase 4Withdrawn

Leveraging EEG for Antidepressant Prediction With Duloxetine and Bupropion

Role: lead

NCT04388202Phase 4Withdrawn

Leveraging EEG for Antidepressant Prediction With Sertraline and Escitalopram

Role: lead

All 12 trials loaded